Combination treatment for sleep disorders including sleep apnea
First Claim
Patent Images
1. A pharmaceutical composition for the treatment of sleep disorders including sleep apnea in a mammal, comprising:
- (a) a compound that exhibits activity, respectively, as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
(b) a 5HT1a antagonist or an alpha-2-adrenergic antagonist or pharmaceutically acceptable salt thereof; and
(c) a pharmaceutically acceptable carrier;
wherein the active agents “
a” and
“
b”
above are present in amounts that render the composition effective in treating, respectively, sleep disorders including sleep apnea depression with increased efficacy.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.
31 Citations
30 Claims
-
1. A pharmaceutical composition for the treatment of sleep disorders including sleep apnea in a mammal, comprising:
- (a) a compound that exhibits activity, respectively, as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
(b) a 5HT1a antagonist or an alpha-2-adrenergic antagonist or pharmaceutically acceptable salt thereof; and
(c) a pharmaceutically acceptable carrier;
wherein the active agents “
a” and
“
b”
above are present in amounts that render the composition effective in treating, respectively, sleep disorders including sleep apnea depression with increased efficacy. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- (a) a compound that exhibits activity, respectively, as an SRI antidepressant, or a pharmaceutically acceptable salt thereof;
-
22. A method of treating sleep disorder including sleep apnea in a mammal, comprising administering to said mammal:
- (a) a compound that exhibits activity as an SRIantidepressant, or a pharmaceutically acceptable salt thereof; and
(b) a 5HT1a antagonist or an alpha-2-adrenergic antagonist or pharmaceutically acceptable salt thereof;
wherein the active agents “
a” and
“
b”
above are present in amounts that render the combination of the two agents effective in treating, respectively, sleep disorder with increased efficacy. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30)
- (a) a compound that exhibits activity as an SRIantidepressant, or a pharmaceutically acceptable salt thereof; and
Specification